MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerThomas Powles, Nicholas J. Vogelzang, Xiaodong Shen et al.|Nature|2014Cited by 2.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun Vasant Balar, Dean F. Bajorin, Matthew D. Galsky et al.|The Lancet|2016Cited by 2.2k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Alain Ravaud, Ignacio Durán et al.|The Lancet|2017Cited by 1.4k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumabDavid R. Gandara, David S. Shames, Sarah Paul et al.|Nature Medicine|2018Cited by 1.2k
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacyLeisa Johnson, Priti S. Hegde|Journal of Clinical Investigation|2013Cited by 37